Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Huntington's disease (HD) is a progressive neurodegenerative disorder, the pathomechanism of which is not yet fully understood. Excitotoxicity is known to be involved in the development of HD and antiglutamatergic agents may, therefore, have beneficial neuroprotective effects. One of these agents is the tryptophan metabolite kynurenic acid (KYNA), which is an endogenous NMDA receptor antagonist. However, its pharmacological properties rule out its systemic administration in CNS disorders. We have tested a novel KYNA analogue, N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride, in the N171-82Q transgenic mouse model of HD. The analogue exhibited several significant effects: it prolonged the survival of the transgenic mice, ameliorated their hypolocomotion, prevented the loss of weight and completely prevented the atrophy of the striatal neurons. The beneficial effects of this KYNA analogue are probably explained by its complex anti-excitotoxic activity. As it did not induce any appreciable side-effect at the protective dose applied in a chronic dosing regime in this mouse model, it appears worthy of further thorough investigations with a view to eventual clinical trials.

Original languageEnglish
Pages (from-to)865-875
Number of pages11
JournalJournal of neural transmission
Volume118
Issue number6
DOIs
Publication statusPublished - Jun 1 2011

Keywords

  • Huntington's disease
  • Kynurenic acid analogue
  • N171-82Q
  • Neuroprotection
  • Stereology
  • Transgenic mice

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease'. Together they form a unique fingerprint.

  • Cite this